Ann Otol Rhinol Laryngol. 2026 Jan 7:34894251401132. doi: 10.1177/00034894251401132. Online ahead of print.
ABSTRACT
OBJECTIVE: To assess the effect of rhinophototherapy (RPT) on nasal mucosa and inflammatory cells in allergic rhinitis compared to intranasal corticosteroids (INCS).
METHODS: Adult patients (≥18 years) with newly diagnosed perennial allergic rhinitis (AR) were randomly divided into 2 groups, RPT and INCS. Treatment was administered for 2 weeks. Primary outcome was evaluation of the inflammatory cells and mucosal damage via inferior turbinate biopsy, performed post-treatment. Secondary outcomes measured were visual analogue score (VAS) of clinical symptoms (overall, runny nose, sneezing, nasal block, nasal itchiness and ocular itchiness) and nasal patency using rhinomanometry and peak nasal inspiratory flow (PNIF).
RESULTS: Thirty-five patients were included, with 18 patients randomized into RPT and 17 patients into INCS. The mean age of patients was 31.3 ± 9.6 (range: 19-57). There was no statistically significant difference observed in terms of inflammatory cells in both groups. Similarly, both groups had no differences in mucosal damage parameters. Patients in RPT group showed statistically significant improvement for overall and specific symptoms VAS score (P < 0.05). Comparing both groups, patients using INCS reported bigger effect size for overall VAS score and specific VAS score for runny nose, sneezing, nasal and eye itchiness. Both groups showed improvement in PNIF reading post-treatment although only RPT group showed statistical significance (P = .015). In terms of rhinomanometry, both groups showed significant improvement in post-treatment nasal flow rate (P < .05). There was decrease in total nasal resistance observed in both groups, albeit with RPT being statistically significant (P = .004). There were no adverse events reported in both groups.
CONCLUSION: There is no significant difference in inflammatory cells of inferior turbinate mucosa and mucosal damage between RPT and INCS. RPT is a safe and suitable short-term alternative (2 weeks) for AR patients who are contraindicated for or unable to tolerate INCS.
CLINICAL TRIAL NUMBER: The study was registered with ClinicalTrials.gov with the ID: NCT05919316.
PMID:41501617 | DOI:10.1177/00034894251401132
